Genetic polymorphisms in S100B [32] and receptor for advanced glycation end-product genes in schizophrenia cohorts (Table 2) [32,33,205] suggest these abnormalities are likely primary/pathogenic rather than secondary/biomarkers. This evidence concerns the gene S100B and schizophrenia.